Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.

Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H.

Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.

Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.

Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.

Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.

Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Szamosi J, Earley W, Eriksson H.

Int J Neuropsychopharmacol. 2013 Sep;16(8):1733-44. doi: 10.1017/S146114571300028X. Epub 2013 May 14. Erratum in: Int J Neuropsychopharmacol. 2015;18(2). pii: pyu086. doi: 10.1093/ijnp/pyu086. Papakosts, George I [corrected to Papakostas, George I]. Int J Neuropsychopharmacol. 2015 Jul;18(9). pii: pyv056. doi: 10.1093/ijnp/pyv056.

The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.

Dording C, Cassiello C, King F 4th, Pencina M, Fava M, Mischoulon D.

Int Clin Psychopharmacol. 2013 Sep;28(5):238-44.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol.

Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol.

2013 May;28(3):113-20. doi: 10.1097/YIC.0b013e32835fb971.

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.

Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M.

J Psychopharmacol. 2013 May;27(5):424-34.

An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): a possible role for neurogenesis in drug discovery.

Fava M, Targum SD, Nierenberg AA, Bleicher LS, Carter TA, Wedel PC, Hen R, Gage FH, Barlow C.

J Psychiatr Res. 2012 Dec;46(12):1553-63.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial.

Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M.

J Psychiatr Res. 2012 Jan;46(1):64-71.

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012 Jan 25;81(2):87-97.